Genetically-engineered pig organ transplantation in baboons: immunological and functional studies
狒狒基因工程猪器官移植:免疫学和功能研究
基本信息
- 批准号:10621195
- 负责人:
- 金额:$ 157.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-08-01 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:Antigen TargetingClinical TrialsDestinationsDoctor of PhilosophyEndothelial CellsFamily suidaeFat emulsionFundingGenesGeneticGenetic EngineeringGoalsGraft SurvivalGrowth Hormone ReceptorHeartHeart TransplantationHistopathologyHumanImmune responseImmunobiologyImmunologicsImmunology procedureInfusion proceduresInnate Immune ResponseInterventionKidneyKupffer CellsLifeLiverMethodsMitochondriaModelingModificationMonitorMyocardiumOrganOrgan TransplantationOrgan failurePapioPatientsPhagocytosis InhibitionPreservation TechniquePrimatesProceduresRegimenRenal functionResearchScienceSourceTechniquesTherapeuticTherapeutic immunosuppressionThrombocytopeniaTransgenesTransplantationTriiodothyronineWorkXenograft procedureadaptive immune responseallotransplantclinical applicationgenetic manipulationgraft failureheart functionimprovedliver functionliver transplantationnatural antibodiesnonhuman primatenovelorgan growthorgan injuryorganizational structurepharmacologicpreventprogramsrapid growthsuccess
项目摘要
GENETICALLY-ENGINEERED PIG ORGAN TRANSPLANTATION IN BABOONS: IMMUNOLOGICAL
AND FUNCTIONAL STUDIES (PI/PD: David K.C. Cooper)
OVERVIEW OF THE PROGRAM
PROJECT SUMMARY/ABSTRACT
Our program has produced genetically-engineered pigs that protect the pig organ from injury by
the primate innate immune response. Organs transplanted from these pigs, together with an effective
(and potentially clinically-applicable) immunosuppressive regimen, have markedly extended pig graft
survival in baboons to months or even years. The current proposal aims to confirm that the combination
of a multi-gene pig and an effective immunosuppressive regimen will allow consistent function of life-
supporting pig kidneys (Project 1) and hearts (Project 3) for 6 months or longer, and of life-supporting
livers for 1 month (to act as a bridge to liver allotransplantation [Project 2]). The work in the 3 Projects
will be supported by 4 Cores.
Core A (Pig Core) will provide specific multi-gene pigs (to Projects 1-3) that have 8 or more genetic
manipulations that will help overcome the remaining barriers to moving towards clinical trials. Core B
(Immunobiology Core) and Core C (Histopathology Core) will provide evidence of the mechanisms for
the problems being investigated and the therapeutic approaches being explored. Core D (Administrative
Core) will provide an organizational structure to facilitate the success of the proposed Projects.
Our Aims include (i) exploring methods of preventing or suppressing the adaptive immune
response through either novel pig genetics or pharmacologic interventions, (ii) preventing or reducing the
thrombocytopenia that immediately follows pig liver transplantation in baboons, (iii) preventing or
reducing the rapid growth of pig organs documented early after transplantation into baboons, and (iv)
comprehensively monitoring function of the kidney, liver, and heart after transplantation into baboons in
the presence of a controlled immune response (i.e., in the relative absence of an immune response). The
mechanisms whereby the combination of genetic modification and refinements to the
immunosuppressive regimen prolong graft survival will be investigated by immunological assays and
histopathology techniques.
Success in Projects 1 and 3 would allow immediate consideration of limited clinical trials of kidney
and/or heart xenotransplantation. Success in Project 2 would allow immediate consideration of a limited
clinical trial in which a pig liver is transplanted as a life-sustaining bridge to allotransplantation. The
overall goal of the 3 projects, therefore, is to advance the science during this 5-year period of funding so
that clinical trials of kidneys and hearts can be initiated as destination therapies (or, in the case of the
heart, possibly initially as a bridging therapy), and of pig livers as bridging to allotransplantation.
基因工程猪器官移植在狒狒体内的免疫学研究
和功能研究(PI/PD:David K.C.Cooper)
该计划概述
项目摘要/摘要
我们的项目已经培育出基因工程猪,通过以下方式保护猪器官免受伤害
灵长类的先天免疫反应。从这些猪身上移植的器官,连同一个有效的
(可能在临床上适用的)免疫抑制方案显著延长了猪的移植物
狒狒的存活时间可达数月甚至数年。目前的提案旨在确认这一组合
多基因猪和有效的免疫抑制方案将允许生命的持续功能-
支持猪肾(项目1)和心脏(项目3)6个月或更长时间,以及维持生命
肝脏移植1个月(作为同种异体肝移植的桥梁[项目2])。3个项目中的工作
将由4个内核支持。
核心A(猪核心)将提供具有8个或更多基因的特定多基因猪(至项目1-3)
将有助于克服迈向临床试验的剩余障碍的操纵。核心B
(免疫生物学核心)和核心C(组织病理学核心)将提供机制的证据
正在调查的问题和正在探索的治疗方法。核心D(管理
(核心)将提供一个组织结构,以促进拟议项目的成功。
我们的目标包括:(1)探索预防或抑制获得性免疫的方法
通过新的猪遗传学或药物干预反应,(Ii)预防或减少
(Iii)预防和预防:(I)预防和预防;(Ii)预防和预防;
减少猪器官移植到狒狒体内后早期记录的快速生长,以及(Iv)
猕猴移植后肾、肝、心功能的综合监测
受控免疫反应的存在(即相对缺乏免疫反应)。这个
基因修改和精炼相结合的机制
免疫抑制方案延长移植物存活将通过免疫学分析和
组织病理学技术。
项目1和3的成功将使人们能够立即考虑有限的肾脏临床试验。
和/或异种心脏移植。在项目2中取得成功将允许立即考虑有限的
将猪的肝脏移植作为同种异体移植的生命桥梁的临床试验。这个
因此,这3个项目的总体目标是在这5年的资金支持期间推动科学的发展
肾脏和心脏的临床试验可以作为目标疗法启动(或者,在
心脏移植最初可能是一种搭桥疗法),猪肝作为同种异体移植的搭桥。
项目成果
期刊论文数量(123)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Is interleukin-6 receptor blockade (tocilizumab) beneficial or detrimental to pig-to-baboon organ xenotransplantation?
- DOI:10.1111/ajt.15712
- 发表时间:2020-01-03
- 期刊:
- 影响因子:8.8
- 作者:Zhang, Guoqiang;Iwase, Hayato;Hara, Hidetaka
- 通讯作者:Hara, Hidetaka
Xenotransplantation-A Basic Science Perspective.
- DOI:10.34067/kid.0000000000000173
- 发表时间:2023-08-01
- 期刊:
- 影响因子:0
- 作者:Cooper DKC;Hara H
- 通讯作者:Hara H
Patient informed consent for a clinical trial of gene-edited pig kidney transplantation: A representative consent form.
基因编辑猪肾移植临床试验的患者知情同意书:代表性同意书。
- DOI:10.1111/xen.12790
- 发表时间:2023
- 期刊:
- 影响因子:3.9
- 作者:Cooper,DavidKC
- 通讯作者:Cooper,DavidKC
A Standardized Approach to Orthotopic (Life-supporting) Porcine Cardiac Xenotransplantation in a Nonhuman Primate Model.
非人灵长类动物模型中原位(维持生命)猪心脏异种移植的标准化方法。
- DOI:10.1097/tp.0000000000004508
- 发表时间:2023
- 期刊:
- 影响因子:6.2
- 作者:Goerlich,CorbinE;Griffith,BartleyP;Shah,Aakash;Treffalls,JohnA;Zhang,Tianshu;Lewis,Billeta;Tatarov,Ivan;Hershfeld,Alena;Sentz,Faith;Braileanu,Gheorghe;Ayares,David;Singh,AvneeshK;Mohiuddin,MuhammadM
- 通讯作者:Mohiuddin,MuhammadM
Genetically engineered pig kidney transplantation in a brain-dead human subject.
- DOI:10.1111/xen.12718
- 发表时间:2021-11
- 期刊:
- 影响因子:3.9
- 作者:Cooper DKC
- 通讯作者:Cooper DKC
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID KC COOPER其他文献
DAVID KC COOPER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID KC COOPER', 18)}}的其他基金
Alemtuzumab and Regulatory T Cells for Heart Transplant Tolerance in Monkeys
阿仑单抗和调节性 T 细胞对猴子心脏移植耐受的影响
- 批准号:
8111828 - 财政年份:2010
- 资助金额:
$ 157.68万 - 项目类别:
Genetically-engineered pig organ transplantation into nonhuman primates
基因工程猪器官移植到非人类灵长类动物中
- 批准号:
8116016 - 财政年份:2010
- 资助金额:
$ 157.68万 - 项目类别:
Genetically-engineered pig organ transplantation into nonhuman primates
基因工程猪器官移植到非人类灵长类动物中
- 批准号:
8711224 - 财政年份:2010
- 资助金额:
$ 157.68万 - 项目类别:
Genetically-engineered pig kidney transplantation in baboons: reducing the adaptive immune response and monitoring graft function
狒狒基因工程猪肾移植:降低适应性免疫反应并监测移植物功能
- 批准号:
10019098 - 财政年份:2010
- 资助金额:
$ 157.68万 - 项目类别:
Genetically-engineered Pig Organ Transplantation into Non-human Primates
基因工程猪器官移植到非人类灵长类动物中
- 批准号:
9115981 - 财政年份:2010
- 资助金额:
$ 157.68万 - 项目类别:
Alemtuzumab and Regulatory T Cells for Heart Transplant Tolerance in Monkeys
阿仑单抗和调节性 T 细胞对猴子心脏移植耐受的影响
- 批准号:
8487350 - 财政年份:2010
- 资助金额:
$ 157.68万 - 项目类别:
Genetically-engineered pig organ transplantation into nonhuman primates
基因工程猪器官移植到非人类灵长类动物中
- 批准号:
8309417 - 财政年份:2010
- 资助金额:
$ 157.68万 - 项目类别:
Genetically-engineered pig organ transplantation into nonhuman primates
基因工程猪器官移植到非人类灵长类动物中
- 批准号:
7997529 - 财政年份:2010
- 资助金额:
$ 157.68万 - 项目类别:
Genetically-engineered pig organ transplantation in baboons: immunological and functional studies
狒狒基因工程猪器官移植:免疫学和功能研究
- 批准号:
10019093 - 财政年份:2010
- 资助金额:
$ 157.68万 - 项目类别:
相似海外基金
From lymphatics to evaluating resolution therapeutics in clinical trials
从淋巴管到评估临床试验中的解决疗法
- 批准号:
MR/Y013050/1 - 财政年份:2024
- 资助金额:
$ 157.68万 - 项目类别:
Fellowship
RareKids-CAN: Pediatric Rare Disease Clinical Trials and Treatment Network
RareKids-CAN:儿科罕见病临床试验和治疗网络
- 批准号:
495575 - 财政年份:2023
- 资助金额:
$ 157.68万 - 项目类别:
Operating Grants
Unbiased estimation in hierarchical models for Clinical trials
临床试验分层模型中的无偏估计
- 批准号:
2884930 - 财政年份:2023
- 资助金额:
$ 157.68万 - 项目类别:
Studentship
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 157.68万 - 项目类别:
NIDA Clinical Trials Network: New York Node
NIDA 临床试验网络:纽约节点
- 批准号:
10855627 - 财政年份:2023
- 资助金额:
$ 157.68万 - 项目类别:
CCTN-CONTRACEPTIVE DEVELOPMENT PROGRAM-NICHD CONTRACEPTIVE CLINICAL TRIALS NETWORK-FEMALE SITES-CORE FUNCTION ACTIVITIES
CCTN-避孕发展计划-NICHD避孕临床试验网络-女性站点-核心功能活动
- 批准号:
10895949 - 财政年份:2023
- 资助金额:
$ 157.68万 - 项目类别:
CONTRACEPTIVE CLINICAL TRIALS NETWORK, CCTN - FEMALE SITES 'CORE FUNCTION ACTIVITIES
避孕临床试验网络,CCTN - 女性站点的核心功能活动
- 批准号:
10891325 - 财政年份:2023
- 资助金额:
$ 157.68万 - 项目类别:
ISimcha Technology Platform for Recruiting a Diverse Population of Older Adults into Clinical Trials
ISimcha 技术平台,用于招募不同的老年人群进行临床试验
- 批准号:
10761602 - 财政年份:2023
- 资助金额:
$ 157.68万 - 项目类别:
Implementing HIV/Cervical Cancer Prevention CASCADE Clinical Trials in Zimbabwe (ZIM-CASCADE)
在津巴布韦实施艾滋病毒/宫颈癌预防 CASCADE 临床试验 (ZIM-CASCADE)
- 批准号:
10758129 - 财政年份:2023
- 资助金额:
$ 157.68万 - 项目类别:














{{item.name}}会员




